Horizon Therapeutics plc Expands Medidata Partnership
Medidata has announced its expanded partnership with Horizon Therapeutics plc. Starting with one technology solution, Medidata will provide a suite of solutions for Horizon’s clinical research needs in multiple therapeutic areas including ophthalmology, rheumatology, and nephrology.
Horizon will access a broad range of clinical trial solutions using the Medidata Rave Clinical Cloud. Horizon will use Medidata’s Intelligent Trials product, which brings artificial intelligence, partnered with advanced analytics, to bring cross-industry real-time performance metrics, predictive models, and forecasting capabilities for trial planning and execution.
For more information, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
